• vcard
D 312.463.6353
F 312.819.1910
  • Education
    • J.D., Duke University School of Law, 1995
    • B.A., University of California, Berkeley, 1991
  • Court Admissions
    • State of Illinois
    • United States Supreme Court, 2001
    • United States Court of Appeals for the Federal Circuit
    • U.S. Court of Appeals, Seventh Circuit
    • U.S. District Court, Northern District of Illinois, 1995
Taras Gracey is a trial lawyer with more than 20 years of courtroom experience. He has tried both jury and bench trials as well as handled numerous appeals in the Federal and Seventh Circuits. He has represented both patent owners and accused infringers in a broad spectrum of intellectual property disputes, focusing on pharmaceutical/Hatch-Waxman litigation and technology matters involving chipsets and display technologies. He also is versed in and has handled inter partes reviews (IPRs). Taras' litigation experience spans the country, including federal courts in California, Delaware, Illinois, New Jersey, New York, and Texas.

On the patent owner side, Taras has won a jury verdict of over $20 million in one technology case and obtained a $35 million settlement on the last day of trial in another. On the Hatch-Waxman side, he has successfully first-chaired numerous cases and was part of the team that invalidated Eli Lilly's patent on Prozac®, which the press called "the Mother of All Patent Challenges." 
  • Represented pharmaceutical client in Hatch-Waxman patent infringement disputes regarding budesonide inhalation suspension for treatment of asthma in children.
  • Represented pharmaceutical client in Hatch-Waxman patent infringement dispute regarding galantamine drug for treatment of Alzheimer's.
  • Represented pharmaceutical client in Hatch-Waxman patent infringement dispute regarding extended release galantamine drug for treatment of Alzheimer's.
  • Represented pharmaceutical client in Hatch-Waxman patent infringement dispute regarding triamcinolone acetonide drug for treatment of allergies.
  • Represented pharmaceutical client in Hatch-Waxman patent infringement dispute regarding fluoxetine hydrochloride drug for treatment of depression.
  • Represented pharmaceutical client in Hatch-Waxman patent infringement dispute regarding temozolomide drug for treatment of brain cancer.
  • Represented pharmaceutical client in Hatch-Waxman patent infringement dispute regarding niacin drug for treatment of dyslipidemia.
  • Represented technology company in multiple patent infringement disputes regarding computer chipset technology.
  • Represented semiconductor company in patent infringement dispute regarding display technology. 
  • Represented electronics company in patent infringement dispute regarding display technology. 
  • Represented agricultural company in antitrust dispute regarding high fructose corn syrup.
  • Represented utility company in toxic tort dispute regarding manufactured gas plant.
text icon Publications & Presentations
October 2, 2018
text icon Publications & Presentations
Co-Presenter, ACI Paragraph IV Disputes Master Symposium; Chicago, IL
October 2, 2017
text icon Publications & Presentations
Economic Motives of IPRs are not an "Abuse of Process"
Author; AIA Post Grant Proceedings
November 4, 2015
text icon Publications & Presentations
Rejection of Invalidity Defenses at District Court Did Not Prohibit PTAB's Later Finding of Unpatentability
Author; AIA Post Grant Proceedings
February 11, 2014
text icon Publications & Presentations
All is not Lost for Patent Owner After the First Written Decision in an IPR Favoring Petitioner
Author; AIA Post Grant Proceedings
December 20, 2013